Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04697446
Status:
UNKNOWN
Last Update Posted:
2021-08-10
First Post:
2020-12-16
Brief Title:
External Control Observational Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Sponsor:
Blueprint Medicines Corporation
Organization:
Blueprint Medicines Corporation
Conditions & Keywords Data
Conditions:
| Name |
|---|
| RET-fusion Non Small Cell Lung Cancer |
| Lung Neoplasm |
| Carcinoma Non-Small-Cell Lung |
| Respiratory Tract Neoplasms |
| Thoracic Neoplasms |
| Neoplasms by Site |
| Neoplasms |
| Lung Diseases |
| Respiratory Tract Diseases |
| Carcinoma Bronchogenic |
| Bronchial Diseases |
| Head and Neck Neoplasms |
| Carcinoma |
| Neoplasms by Histologic Type |
| Neoplasms Germ Cell and Embryonal |
| Neoplasms Nerve Tissue |
| Metastatic Non Small Cell Lung Cancer |
Keywords: